Cardiff Oncology (CRDF, Financial) has recently attracted attention from the investment community as Ladenburg Thalmann, a financial services firm, initiated coverage on the stock. The analyst responsible for this new coverage, Kevin DeGeeter, has provided a "Buy" rating for CRDF, reflecting a positive outlook for the company's future performance.
The announcement was made on July 8, 2025, and highlights a price target of $19.00 USD for Cardiff Oncology. This price target is the first set by Ladenburg Thalmann for CRDF, as there was no prior target reported. The analyst's coverage initiation implies a favorable view of Cardiff Oncology's growth prospects and market potential.
As a key player in the biotechnology sector, Cardiff Oncology focuses on developing innovative cancer treatments. The "Buy" rating from Kevin DeGeeter indicates confidence in the company's strategic direction and its ability to achieve significant clinical milestones.
Investors and market participants may consider this new coverage and price target as influential factors when evaluating their investment strategies related to Cardiff Oncology (CRDF, Financial).
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Cardiff Oncology Inc (CRDF, Financial) is $11.10 with a high estimate of $18.00 and a low estimate of $3.50. The average target implies an upside of 180.66% from the current price of $3.96. More detailed estimate data can be found on the Cardiff Oncology Inc (CRDF) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Cardiff Oncology Inc's (CRDF, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Cardiff Oncology Inc (CRDF, Financial) in one year is $2.86, suggesting a downside of 27.69% from the current price of $3.955. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Cardiff Oncology Inc (CRDF) Summary page.
